CHI and Bio-IT World Present the Thirteenth Annual Structure-Based Drug Design: Genome to Drug Lead with Big Data Approach conference, June 19-21, 2013, Boston, MA, will cover developments in in silico technology, as well as experimental approaches useful

Recent advances in cancer immunotherapy have turned researcher' s attentions to new therapeutic strategies focused on improved specificity, control of key checkpoints in immune response, the identification of new biomarkers and novel ways of combining the

In this DVD, we will provide a baseline understanding of the regulatory need, common practices and real world examples of integrating Human Factors Engineering into a drug development activity. Key topics to be addressed: Why you should care: Regulatory expectations for the application of HFE What to avoid: Right and wrong ways to apply HFE to your project Lessons from the field: Real world examples of HFE

This course will address the questions on “why should I care about kinetics?” and “how can I understand and predict Structure-Kinetics relationships?” We will first review the role of binding kinetics in drug action and then focus on the particular case of protein-ligand non-covalent complexes, reviewing what is known so far about the structural determinants of binding kinetics. This course will help you with a better understanding and increased awareness of current state of the chemistry and pharmacology of binding kinetics.

The advancing technology of high-throughput screening is changing the type of molecules found. With protein function more physiologically relevant, the quality of the molecules that pharmacologists and medicinal chemists must deal with is changing. This course will familiarize researchers with the tools needed to exploit this potentially fruitful area of new drug discovery through discussion of allosteric molecules, detection of allosterism, and quantifying allosterism for chemical lead optimization.